Patents by Inventor Stanislav Rudolfovich EVDOKIMOV

Stanislav Rudolfovich EVDOKIMOV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOCYTOKINE FOR ACTIVATING HUMAN IL-10RA RECEPTOR AND USE THEREOF
    Publication number: 20240034764
    Abstract: The present invention relates to the field of biotechnology and medicine, in particular to an immunocytokine for activating the human IL-10R? receptor. The invention further relates to nucleic acids encoding said immunocytokine, expression vectors, host cells and methods for producing same, methods for producing the immunocytokine, pharmaceutical compositions comprising the above immunocytokine, pharmaceutical compositions comprising the above immunocytokine and other therapeutically active compounds, methods for treating an oncological disease and the uses of the immunocytokine or pharmaceutical compositions thereof for treating an oncological disease.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 1, 2024
    Inventors: Aleksey Vladimirovich KONONOV, Iuliia Viktorovna EVDOKIMOVSKAIA, Iana Andreevna SMIRNOVA, Stanislav Rudolfovich EVDOKIMOV, Elena Sergeevna KOLOSOVA, Sergei Andreevich AGEEV, Vladimir Sergeevich TSYMPILOV, Valery Vladimirovich SOLOVYEV, Pavel Andreevich IAKOVLEV, Dmitry Valentinovich MOROZOV
  • IMMUNOCYTOKINE COMPRISING HETERODYMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15RA
    Publication number: 20230011234
    Abstract: The present invention relates to an immunocytokine comprising an heterodimeric protein complex based on IL-15/IL-15R?, and to use thereof as a therapeutic agent, in particular as an agent for the treatment of cancer and an autoimmune disease. The present invention further relates to an immunocytokine comprising a heterodimeric protein complex based on an IL-15/IL-15R? and an immunomodulatory antibody, and to use thereof as a therapeutic agent, in particular as an agent for the treatment of cancer and an autoimmune disease.
    Type: Application
    Filed: September 20, 2020
    Publication date: January 12, 2023
    Inventors: Andrei Borisovich ULITIN, Aleksey Vladimirovich KONONOV, Sergei Andreevich AGEEV, Aleksandr Andreevich GORDEEV, Elena Vladimirovna VINOGRADOVA, Stanislav Rudolfovich EVDOKIMOV, Aleksandra Pavlovna SHMAKOVA, Ivan Vladimirovich MITROSHIN, Dmitry Valentinovich MOROZOV
  • Method for treatment of an IL-17A-mediated disease through antibody administration specific to human IL-17A
    Patent number: 11447574
    Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: September 20, 2022
    Inventors: Andrey Borisovich Ulitin, Stanislav Rudolfovich Evdokimov, Valeriy Vladimirovich Soloviev, Yulia Sergeevna Chernykh, Olga Vladimirovna Goncharova, Dmitriy Valerievich Korzhavin, Tatyana Veniaminovna Chernovskaya, Timofey Aleksandrovich Nemankin, Roman Alexeevich Ivanov, Dmitriy Valentinovich Morozov, Victoria Mikhailovna Ekimova, Ekaterina Vladimirovna Sofronova, Yakov Yurevich Ustyugov
  • HIGH AFFINITY AND AGGREGATIVELY STABLE ANTIBODIES ON THE BASIS OF VARIABLE DOMAINS VL AND A DERIVATIVE VHH
    Publication number: 20200031952
    Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.
    Type: Application
    Filed: September 9, 2019
    Publication date: January 30, 2020
    Inventors: Andrey Borisovich ULITIN, Stanislav Rudolfovich EVDOKIMOV, Valeriy Vladimirovich SOLOVIEV, Yulia Sergeevna CHERNYKH, Olga Vladimirovna GONCHAROVA, Dmitriy Valerievich KORZHAVIN, Tatyana Veniaminovna CHERNOVSKAYA, Timofey Aleksandrovich NEMANKIN, Roman Alexeevich IVANOV, Dmitriy Valentinovich MOROZOV, Victoria Mikhailovna EKIMOVA, Ekaterina Vladimirovna SOFRONOVA, Yakov Yurevich USTYUGOV
  • Anti-IL-17 antibodies
    Patent number: 10442857
    Abstract: The present invention relates to the field of medicine, and specifically to the field of monoclonal antibodies against human IL-17. More specifically, the invention relates to monoclonal antibodies/antagonists of IL-17A, which bind with high affinity to an IL-17 epitope, wherein the antibodies contain amino acid substitutions in hypervariable regions of heavy and light chains. The antibodies according to this invention can be chimeric, humanized or human antibodies or antigen-binding fragments thereof, and can be used as a medicinal agent for treating autoimmune and inflammatory disorders and disorders of cell proliferation and development. The invention also relates to methods for producing said antibodies.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: October 15, 2019
    Assignee: CLOSED JOINT STOCK COMPANY “BIOCAD”
    Inventors: Andrey Borisovich Ulitin, Stanislav Rudolfovich Evdokimov, Valeriy Vladimirovich Soloviev, Yulia Sergeevna Chernyh, Olga Vladimirovna Goncharova, Dmitriy Valerievich Korzhavin, Tatyana Veniaminovna Chernovskaya, Roman Alexeevich Ivanov, Dmitriy Valentinovich Morozov
  • Anti-IL-17A Antibodies
    Patent number: 10442869
    Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: October 15, 2019
    Assignee: CLOSED JOINT STOCK COMPANY “BIOCAD”
    Inventors: Andrey Borisovich Ulitin, Stanislav Rudolfovich Evdokimov, Valeriy Vladimirovich Soloviev, Yulia Sergeevna Chernyh, Olga Vladimirovna Goncharova, Dmitriy Valerievich Korzhavin, Tatyana Veniaminovna Chernovskaya, Timofey Aleksandrovich Nemankin, Roman Alexeevich Ivanov, Dmitriy Valentinovich Morozov, Victoria Mikhailovna Ekimova, Ekaterina Vladimirovna Sofronova, Yakov Yurevich Ustyugov
  • ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF CAPABLE OF BINDING TO A HUMAN RECEPTOR OF INTERLEUKIN-6
    Publication number: 20190194313
    Abstract: The invention relates to medicine. The problem addressed by the present invention consists in creating alternative antibodies or fragments thereof which are capable of specifically binding to a human receptor of interleukin-6 and which would be useful as drugs for treating or diagnosing diseases, or for relieving symptoms, mediated by interleukin-6.
    Type: Application
    Filed: August 3, 2017
    Publication date: June 27, 2019
    Inventors: Stanislav Rudolfovich EVDOKIMOV, Andrei Borisovich ULITIN, Valery Vladimirovich SOLOVYEV, Aleksei Aleksandrovich ALEKSANDROV, Yulia Sergeevna CHERNYKH, Timofey Aleksandrovich NEMANKIN, Anna Konstantinovna VLADIMIROVA, Oleg Igorevich SMOTROV, Tatiana Veniaminovna CHERNOVSKAYA, Aleksandr Aleksandrovich MOSHCHENKO, Viktoriia Evgenevna NALOBINA, Roman Alekseevich IVANOV, Dmitry Valentinovich MOROZOV
  • ANTI-IL-17 ANTIBODIES, METHOD FOR PRODUCING SAME AND METHOD FOR USING SAME
    Publication number: 20170081401
    Abstract: The present invention relates to the field of medicine, and specifically to the field of monoclonal antibodies against human IL-17. More specifically, the invention relates to monoclonal antibodies/antagonists of IL-17A, which bind with high affinity to an IL-17 epitope, wherein the antibodies contain amino acid substitutions in hypervariable regions of heavy and light chains. The antibodies according to this invention can be chimeric, humanized or human antibodies or antigen-binding fragments thereof, and can be used as a medicinal agent for treating autoimmune and inflammatory disorders and disorders of cell proliferation and development. The invention also relates to methods for producing said antibodies.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 23, 2017
    Inventors: Andrey Borisovich ULITIN, Stanislav Rudolfovich EVDOKIMOV, Valeriy Vladimirovich SOLOVIEV, Yulia Sergeevna CHERNYH, Olga Vladimirovna GONCHAROVA, Dmitriy Valerievich KORZHAVIN, Tatyana Veniaminovna CHERNOVSKAYA, Roman Alexeevich IVANOV, Dmitriy Valentinovich MOROZOV
  • HIGH AFFINITY AND AGGREGATIVELY STABLE ANTIBODIES ON THE BASIS OF VARIABLE DOMAINS VL AND A DERIVATIVE VHH
    Publication number: 20170066843
    Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 9, 2017
    Inventors: Andrey Borisovich ULITIN, Stanislav Rudolfovich EVDOKIMOV, Valeriy Vladimirovich SOLOVIEV, Yulia Sergeevna CHERNYH, Olga Vladimirovna GONCHAROVA, Dmitriy Valerievich KORZHAVIN, Tatyana Veniaminovna CHERNOVSKAYA, Timofey Aleksandrovich NEMANKIN, Roman Alexeevich IVANOV, Dmitriy Valentinovich MOROZOV, Victoria Mikhailovna EKIMOVA, Ekaterina Vladimirovna SOFRONOVA, Yakov Yurevich USTYUGOV